Incidence of malignancies in HIVinfected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study

Clinical Infectious Diseases

Volumn 50, Issue 9, 2010, Pages 1316-1321

  Prosperi, M C F ^a   Cozzi Lepri, A ^k   Castagna, A ^d   Mussini, C ^f   Murri, R ^a   Giacometti, A ^g,h   Torti, C ⁱ   Costantini, A ⁱ   Narciso, P ^b   Ghinelli, F ^j   Antinori, A ^c   D'Arminio Monforte, A ^e  

^a UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^b Istituto di Ricerca e Cura a Carattere Scientifico L Spallanzani   (Spain)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^d Ospedale S Raffaele   (Spain)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^h OSPEDALI RIUNITI   (Italy)

ⁱ UNIVERSITY OF BRESCIA   (Italy)

^j UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; ITALY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; NEOPLASM; PROGNOSIS;

ADULT; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; ITALY; MALE; NEOPLASMS; PROGNOSIS;

EID: 77951020013     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/651688     Document Type: Article

References (25)

1. Patel P, Hanson DL, Sullivan PS, et al; Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008;148(10):728-736.
2. Serraino D, Piselli P, Busnach G, et al; Immunosuppression and Cancer Study Group. Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer 2007;43(14):2117-2123.
3. Engels EA, Pfeiffer RM, Goedert JJ, et al; for the HIV/AIDS Cancer Match Study. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006;20(12):1645-1654.
4. Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDSdefining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003;21(18):3447-3453.
5. Mayor AM, Gómez MA, Ríos-Olivares E, Hunter-Mellado RF. AIDSdefining neoplasm prevalence in a cohort of HIV-infected patients, before and after highly active antiretroviral therapy. Ethn Dis 2008; 18(2 suppl 2):S2189-S2194.
6. Ives NJ, Gazzard BG, Easterbrook PJ. The changing pattern of AIDSdefining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. J Infect 2001;42(2):134-139.
7. Silverberg MJ, Abrams DI. Do antiretrovirals reduce the risk of nonAIDS-defining malignancies? Curr Opin HIV AIDS 2009;4(1):42-51.
8. Pantanowitz L, Dezube BJ. Evolving spectrum and incidence of nonAIDS-defining malignancies. Curr Opin HIV AIDS 2009;4(1):27-34.
9. Clifford GM, Polesel J, Rickenbach M, et al; Swiss HIV Cohort. Cancer risk in the Swiss HIV Cohort Study: associations with immunodefi-ciency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005;97(6);425-432.
10. Baker JV, Peng G, Rapkin J, Abrams DI, et al; Terry Beim Community Programs for Clinical Research on AIDS (CPCRA). CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22(7) :841-848.
11. Reekie J, Mocroft A, Engsig F, et al. Relationship between current level of immunodeficiency and non-AIDS defining malignancies. In: 16th Conference on Retroviruses and Opportunistic Infections (Montreal). 2009. Poster 860a.
12. Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 2009;23:41-50.
13. d'Arminio Monforte A, Abrams D, Pradier C, et al; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. HIVinduced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008;22(16):2143-2153.
14. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008;22(18):2409-2418.
15. Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007; 21 (14): 1957-1963.
16. d'Arminio Monforte A, Cozzi Lepri A, Rezza G, et al; I.CO.N.A. Study Group. Insights into the reasons for discontinuation of the first highly active antiretrovial therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 2000; 14:499-507.
17. Castro KG, Ward JW, Slutsker L, et al. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults, http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm. Published 18 December 2008. Accessed September 2009.
18. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ; ASCCPSponsored Consensus Conference. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002; 287(16):2120-2129.
19. Andersen P, Gill R. Cox's regression model for counting processes, a large sample study. Annals of Statistics 1982;10:1100-1120.
20. R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2008. http://www.R-project.org.
21. Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005; 104:1505-1511.
22. Kesselring A, Gras L, Smit C, de Wolf F, Reiss P, Wit F. Longer duration of exposure to immunodeficiency and detectable viremia both are risk factors for non-AIDS defining malignancies in HIV-1 infected patients on combination antiretroviral therapy. In: Program and abstracts of the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Geneva: International AIDS Society, 2009. Abstract WEAB 104.
23. Marin B, Thiébaut R, Bucher HC, et al; the CASCADE Collaboration. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009;17:1743-1753.
24. Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009;27(6):884-890.
25. d'Arminio Monforte A, Cozzi-Lepri A, Phillips A, et al; Italian Cohort of Antiretroviral-Naive Patients Study Group. Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of Antiretroviral-Naive Patients. J Acquir Immune Defic Syndr 2005;38(4):407-416.